TOP TIERMARKET NEWSWIRE
News & sentiment

INHIBIKASE THERAPEUT Equity (IKT) — News & AI sentiment

INHIBIKASE THERAPEUT Equity (IKT) news roundup. 5 stories in the past week, 8 over 30 days. Average 30-day sentiment is 51.4/100. No insider transactions filed in the last 90 days. No congressional trade disclosures in the last 90 days. Data shown on this page is delayed 4 hours. Real-time access — including the live wire, real-time alerts, the live S&P 500 heatmap, and the AI Top Trades long/short board — is available with a Top Tier Newswire Pro subscription.

Public view, delayed 4h. For real-time news, alerts, AI sentiment and the long/short AI Top Trades board:Open in the live terminal →
24h stories
0
7d stories
5
avg sentiment 48.8/100
30d stories
8
avg sentiment 51.4/100
Insider net (90d)
$0
0 buys · 0 sells
Congress (90d)
0
0 buys · 0 sells

IKT news in the last 24 hours, 7 days, 30 days and 90 days

How much IKT coverage the wire captured in each window, with the average AI sentiment across those stories. Counts are of stories that have cleared the 4-hour public delay.

Time windowIKT storiesAvg AI sentimentRead
Last 24 hours0—no coverage
Last 7 days548.8/100IKT headlines →
Last 30 days851.4/100IKT headlines →
Last 90 days1446.9/100IKT headlines →

Latest stories on IKT

Inhibikase Therapeutics GAAP EPS of -$0.11 in-line
Seeking Alpha52 · neutralearnings
2d ago
2d ago
2d ago
2d ago
2d ago
Jul 29
Jul 23
Jul 23
Jul 14
Jul 14
Jul 14
Jul 14
Jul 2
Jun 29
Open IKT in the live Top Tier Newswire terminal for real-time stories, sentiment, insider + congress alerts, and the AI Top Trades long/short board.Start a 1-day free trial →